David Paez
Overview
Explore the profile of David Paez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
656
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carrasco-Diaz L, Gallardo A, Volta-Duran E, Virgili A, Paez D, Villaverde A, et al.
Int J Nanomedicine
. 2025 Mar;
20:2445-2460.
PMID: 40034221
Background: Colorectal cancer (CRC) has traditionally been treated with genotoxic chemotherapy to activate pro-apoptotic proteins to induce anticancer effects. However, cancer cells develop resistance to apoptosis, which leads to recurrence...
2.
Riera P, Martin-Cullell B, de Dios A, Virgili A, Ramirez L, Paez D
Med Clin (Barc)
. 2025 Jan;
PMID: 39864990
Background And Aim: One third of patients with colorectal cancer (CRC) undergoing chemotherapy develop serious adverse effects. The aim was to monitor toxicities, evaluate quality of life and the usefulness...
3.
Garcia-Alfonso P, Jimenez-Fonseca P, Soto-Alsar J, Baraibar I, Santos C, La Casta A, et al.
Oncologist
. 2024 Nov;
PMID: 39550209
Introduction: The initial SARS-CoV-2 pandemic wave in Spain in 2020 precipitated significant paradigm shifts in gastrointestinal oncology patient management. This study captures the "Zeitgeist" of this period by analyzing adaptive...
4.
Mirallas O, Martin-Cullell B, Navarro V, Vega K, Recuero-Borau J, Gomez-Puerto D, et al.
Lancet Reg Health Eur
. 2024 Nov;
46:101063.
PMID: 39529819
Background: Prognostic factors for ambulatory oncology patients have been described, including Eastern Cooperative Oncology Group (ECOG), tumor stage and malnutrition. However, there is no firm evidence on which variables best...
5.
Martin-Cullell B, Virgili A, Riera P, Fumagalli C, Mirallas O, Pelegrin F, et al.
Br J Surg
. 2024 Mar;
111(3).
PMID: 38488528
Background: Histopathological and molecular features have been proposed to hold prognostic information, but few have been validated. The aim of this retrospective study was to validate the Genetic And Morphological...
6.
Garcia-Carbonero R, Gonzalez Astorga B, Tocino R, Contreras Toledo D, Pericay C, Fernandez Montes A, et al.
Clin Transl Oncol
. 2023 Aug;
26(4):864-871.
PMID: 37651021
Purpose: Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). We aimed to describe the...
7.
Fernandez Montes A, Elez E, de la Haba-Rodriguez J, Paez D, Mendez-Vidal M, Felip E, et al.
Clin Transl Oncol
. 2023 Jun;
26(1):98-108.
PMID: 37316754
Purpose: Growing complexity and demand for cancer care entail increased challenges for Medical Oncology (MO). The Spanish Society of Medical Oncology (SEOM) has promoted studies to provide updated data to...
8.
Martinez D, Quilez-Cutillas A, Jimenez-Labaig P, Sesma A, Tarazona N, Pacheco-Barcia V, et al.
Clin Transl Oncol
. 2022 Nov;
25(3):796-802.
PMID: 36418642
Background: There is a lack of knowledge about the career paths and employment situation of young medical oncologists. The aim of our study was to evaluate the current professional standing...
9.
Vidal J, Fernandez-Rodriguez M, Casadevall D, Garcia-Alfonso P, Paez D, Guix M, et al.
Clin Cancer Res
. 2022 Sep;
29(2):379-388.
PMID: 36074154
Purpose: Chemotherapy plus anti-EGFR is standard first-line therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC), but biomarkers of early response are clinically needed. We aimed to define the utility...
10.
Aparicio J, Virgili Manrique A, Capdevila J, Munoz Boza F, Galvan P, Richart P, et al.
Clin Transl Oncol
. 2022 Jun;
24(11):2155-2165.
PMID: 35761123
Purpose: Panitumumab plus FOLFOX (P-FOLFOX) is standard first-line treatment for RAS wild-type (WT) metastatic colorectal cancer. The value of panitumumab rechallenge is currently unknown. We assessed addition of panitumumab to...